Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Radiopharmaceuticals for Cancers
share announcement

Radiopharmaceuticals for Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 30 December 2024 | Viewed by 1747

Special Issue Editors

Dr. Joseph Lau

E-Mail Website
Guest Editor
Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada
Interests: positron emission tomography; radiopharmaceutical therapy; drug discovery; theranostics; oncology
Dr. Hwan Lee

E-Mail Website
Guest Editor
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Interests: positron emission tomography; somatostatin receptor imaging; targeted radionuclide therapy; alpha particle; auger electron

Special Issue Information

Dear Colleagues,

We are seeing an unprecedented number of radiopharmaceuticals entering clinical settings for the diagnosis and treatment of cancers. The progress in the field is driven by advances in drug development, radioisotope production, synthetic chemistry, instrumentation, and image quantification. Several PET imaging agents targeting the estrogen receptor and prostate-specific membrane antigen have been approved for clinical use in the past two years, and clinical investigation is underway for other promising targets such as the fibroblast-activating protein. From a therapeutic perspective, there is rapid growth and adoption of beta emitters for treatment of neuroendocrine tumor and prostate cancer, and multiple novel radiopharmaceuticals including alpha emitters are on the horizon. Given the significant interest, from both academia and industry, we anticipate this accelerating trend for radiopharmaceutical development to continue. This special issue will highlight recent developments in diagnostic and therapeutic radiopharmaceuticals for cancers from bench to bedside. Original research papers, communications, or review articles are welcome for this Special Issue. 

Dr. Joseph Lau
Dr. Hwan Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiopharmaceutical
  • positron emission tomography
  • single photon emission computed tomography
  • targeted radionuclide therapy
  • dosimetry
  • cancer
  • in vitro and in vivo characterization

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1295 KiB  
Article
Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT
by Hwan Lee, Sarit T. Kipnis, Remy Niman, Sophia R. O’Brien, Jennifer R. Eads, Bryson W. Katona and Daniel A. Pryma
Cancers 2024, 16(1), 200; https://doi.org/10.3390/cancers16010200 - 31 Dec 2023
Cited by 2 | Viewed by 1206
Abstract
Background: Treatment of metastatic neuroendocrine tumors (NET) with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) results in favorable response only in a subset of patients. We investigated the prognostic value of quantitative pre-treatment semi-automatic 68Ga-DOTATATE PET/CT analysis in NET patients treated with [...] Read more.
Background: Treatment of metastatic neuroendocrine tumors (NET) with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) results in favorable response only in a subset of patients. We investigated the prognostic value of quantitative pre-treatment semi-automatic 68Ga-DOTATATE PET/CT analysis in NET patients treated with PRRT. Methods: The medical records of 94 NET patients who received at least one cycle of PRRT at a single institution were retrospectively reviewed. On each pre-treatment 68Ga-DOTATATE PET/CT, the total tumor volume (TTV), maximum tumor standardized uptake value for the patient (SUVmax), and average uptake in the lesion with the lowest radiotracer uptake (SUVmin) were determined with a semi-automatic tumor delineation method. Progression-free survival (PFS) and overall survival (OS) among the patients were compared based on optimal cutoff values for the imaging parameters. Results: On Kaplan–Meier analysis and univariate Cox regression, significantly shorter PFS was observed in patients with lower SUVmax, lower SUVmin, and higher TTV. On multivariate Cox regression, lower SUVmin and higher TTV remained predictive of shorter PFS. Only higher TTV was found to be predictive of shorter OS on Kaplan–Meier and Cox regression analyses. In a post hoc Kaplan–Meier analysis, patients with at least one high-risk feature (low SUVmin or high TTV) showed shorter PFS and OS, which may be the most convenient parameter to measure in clinical practice. Conclusions: The tumor volume and lowest lesion uptake on 68Ga-DOTATATE PET/CT can predict disease progression following PRRT in NET patients, with the former also predictive of overall survival. NET patients at risk for poor outcomes following PRRT can be identified with semi-automated quantitative analysis of 68Ga-DOTATATE PET/CT. Full article
(This article belongs to the Special Issue Radiopharmaceuticals for Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop